Immunosuppressive therapy after human lung transplantation.
- Author:
Ke-jian CAO
1
;
Cheng-xin GAO
;
Yuan QIN
;
Ding-zhong HU
;
Jian-xin SHI
;
Jun YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antibodies, Monoclonal; therapeutic use; Antibodies, Monoclonal, Humanized; Female; Graft Rejection; prevention & control; Humans; Immunoglobulin G; therapeutic use; Immunosuppressive Agents; therapeutic use; Lung Transplantation; Male; Middle Aged; Mycophenolic Acid; analogs & derivatives; therapeutic use; Postoperative Complications; prevention & control; Prednisone; therapeutic use; Tacrolimus; therapeutic use; Treatment Outcome
- From: Chinese Journal of Surgery 2007;45(12):818-821
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo summarize the diagnosis and treatment of acute rejection after lung transplantation and to discuss optimized immunosuppressive therapy.
METHODSBetween November 2002 and June 2006, 16 patients underwent operations on lung transplantation, 7 cases on single-lung transplantation and 9 cases on bilateral-lung transplantation. Immunosuppressive therapy was new triple drug maintenance regimen including tacrolimus (Tac), mycophenolate mofetil (MMF) and steroids, and (or) daclizumab.
RESULTSEight cases in new triple drug maintenance regimen with daclizumab. There is no acute rejection in 6 months. Except 2 of the 8 cases died of early post-lung transplantation sever pulmonary edema and dysfunction, 3 of the rest 6 cases underwent acute rejection incident about 21.4% (3/14).
CONCLUSIONIn this group the new triple drug maintenance regimen including tacrolimus (Tac), mycophenolate mofetil (MMF) and steroids, and (or) daclizumab acquired beneficial effect in preventing acute rejection after lung transplantation.
